

Free Paper Presentation [DAY 2: May 30, 2025 | 15:10-16:30]

Free Paper 1 [Hepato-Biliary and Pancreas Surgery]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP01	692	Development and External Validation of an Online Risk Calculator for Early Mortality after Hepatic Resection in Hepatocellular Carcinoma	Ren-Jie ZHANG	Naval Medical University, China
15:20-15:30	FP02	752	Role of Hepatobiliary Scintigraphy in Predicting Post-Hepatectomy Liver Failure: A Single-Center Cohort Study	Jeong-Moo LEE	Seoul National University
15:30-15:40	FP03	304	Robotic subtotal pancreas head resection with longitudinal pancreaticojejunostomy : A novel minimally invasive procedure for chronic pancreatitis	KALAYARASAN RAJA	JIPMER, India
15:40-15:50	FP04	506	Medical Conflicts and Their Effect on Korean Liver-Related Publications: A 2019–2024 Analysis	Namkee Oh	Sungkyunkwan University
15:50-16:00	FP05	757	Clinical Outcomes and Morbidity Analysis of Right Trisectionectomy or Extended Right Lobectomy for Hepatobiliary Disease	Min-ha CHOI	University of Ulsan
16:00-16:10	FP06	471	The role of neoadjuvant chemotherapy (nCT) in the treatment of patients with resectable pancreatic cancer.	Vervekin Ilya	Pavlov First Saint Petersburg State Medical University, Russia
16:10-16:20	FP07	746	Innovative Artificial Intelligence and Machine Learning Based Spatial Computing AR Navigation for Open, Lap, and Robotic Hepatectomy	Maki SUGIMOTO	Teikyo University, Japan
16:20-16:30	FP08	726	Automated Identification of Critical Structures in Laparoscopic Cholecystectomy with Artificial Intelligence	Jae Hyun KWON	Hallym University

Free Paper 2 [Liver Cancer, Clinical 1]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP09	288	Prognostic impact of tumor-associated endothelial B7-H3 expression in hepatocellular carcinoma	Yunmi Ko	Seoul National University
15:20-15:30	FP10	570	Non-contrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance: A randomized, single-center trial	Hyungjin Rhee	Yonsei University
15:30-15:40	FP11	291	Outcomes by Transarterial Chemoembolization (TACE) Modality from Participants (pts) with Embolization-eligible Hepatocellular Carcinoma (HCC) Treated with Durvalumab (D) + Bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 Subgroup Analysis	Jeong Heo	Pusan National University
15:40-15:50	FP12	40	Clinical Utility of Circulating Tumor DNA in Early-Stage Biliary Tract Cancer Following Curative Resection	James Yu	H. Lee Moffitt Cancer Center, USA
15:50-16:00	FP13	485	Early Changes in Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Tumor Response to Atezolizumab and Bevacizumab in Hepatocellular Carcinoma: A Multicenter Retrospective Study	Young Mi Hong	Pusan National University
16:00-16:10	FP14	462	Comparative Efficacy of Lenvatinib Versus Sorafenib as Sequential Therapies Following Atezolizumab and Bevacizumab treatment in Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study	Jun Sik Yoon	Pusan National University
16:10-16:20	FP15	22	Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma	Jonggi Choi	University of Ulsan
16:20-16:30	FP16	43	Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of HCCs from vascular pseudolesions using a CT radiomics approach	Ijin Joo	Seoul National University

Free Paper 3 [MASLD, Clinical]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP17	329	Metabolic dysfunction-associated fibrosis 5 (MAF-5) Score and the Risk of Liver-Related Events in the General Population	Byeong Geun Song	Sungkyunkwan University
15:20-15:30	FP18	182	Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up	Hye-Lin Kim	Sahmyook University
15:30-15:40	FP19	177	The prognostic impact of statin exposure in metabolic dysfunction-associated steatotic liver disease	Keungmo Yang	The Catholic University of Korea
15:40-15:50	FP20	303	Influence of Skeletal Muscle Loss on CKD Development in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients	Aryoung Kim	Inje University
15:50-16:00	FP21	300	Impact of Menopause on Liver Fibrosis Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease	Sae Kyung Joo	Seoul National University
16:00-16:10	FP22	613	Risk of Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Cardiometabolic Risk Factor Count and Its Longitudinal Changes	Han Ah Lee	Chung-Ang University
16:10-16:20	FP23	97	Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Post-Surgical Outcomes in HBV-Related Hepatocellular Carcinoma	Younghyeon Ahn	University of Ulsan
16:20-16:30	FP24	191	Allyl Nonanoate: A Bile Metabolite and Potential Biomarker for Hepatic Fibrosis in MASLD	Soo Hyeon Lee	Hanyang University

Free Paper 4 [HBV Basic & ALD]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP25	181	Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes	Hyo Young Lee	Hanyang University
15:20-15:30	FP26	615	Circulating Fungal Mycobiome and Lipid Dysregulation induces Mitochondrial Dysfunction mediated Shock in Severe Alcoholic Hepatitis	GAURAV TRIPATHI	ILBS, India
15:30-15:40	FP27	131	Impact of Gastrectomy on the Risk of Alcohol-Related Liver Disease: a Nationwide Population-based Cohort Study in Korea	Sang Yi Moon	Dong-A University
15:40-15:50	FP28	301	Intrahepatic IgA Accumulation Activates Macrophages and Exacerbates Hepatic Inflammation in Alcoholic Liver Disease.	Min Gu Kim	The Catholic University of Korea
15:50-16:00	FP29	337	Circulating HBcrAg Levels reflect transcriptionally active cccDNA and predict advanced fibrosis in HBeAg-negative inactive carriers	Hye Seon Kim	The Catholic University of Korea
16:00-16:10	FP30	106	HBV Core Antigen and Impaired Placental Immunity: A Key Driver of HBV Entry Receptor Expression	Ashish Kumar Vyas	Amrita Research Center Delhi NCR, India
16:10-16:20	FP31	289	Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA	Deok Hwa Seo	DepThe Catholic University of Korea
16:20-16:30	FP32	92	Thiazole-Coumarin-Azomethine Derivatives as Dual TLR7/STING Agonists for Innate Immune Activation in Chronic Hepatitis B: Computational Design and Pharmacokinetic Profiling	Rizki Rachmad Saputra	Universitas Palangka Raya, Indonesia

Free Paper 5 [Acute Liver Failure & DILI]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP33	203	TRAIP alleviates DDC-induced cholestatic liver injury through modulating PI3K/Akt/mTOR signaling	Gangping Feng	Guangxi Medical University, China
15:20-15:30	FP34	148	NOX2 is a Promising Target against Acute Liver Injury by Reversing Oxidative Stress, Mitochondrial Dysfunction and cGAS-STING Pathway-Dictated Inflammatory Response	Chao Sun	Tianjin Medical University, China
15:30-15:40	FP35	563	Plasma derived Exosomes multi-omics analysis classifies bacterial peptide and metabolomic cargo as predictor of early mortality in acute liver failure	Neha Sharma	Institute of Liver and Biliary Sciences, India
15:40-15:50	FP36	463	Genetic polymorphism analysis that associated with metabolism and idiopathic pathway of Antituberculosis drug induced liver injury	Putrya Hawa	Indonesian Defense University, Indonesia
15:50-16:00	FP37	586	N-Acetylcysteine Reduces Mortality and Length of Stay in Adult with Non-Acetaminophen-Induced Acute Liver Failure: Evidence from a Meta-Analysis	Agil Noviar Alvirosa	Muhammadiyah Lamongan Hospital, Indonesia
16:00-16:10	FP38	609	Elevated Plasma Chenodeoxycholic Acid as a Prognostic Marker and Therapeutic Target in Acute Liver Failure: Role of Bacteroides intestinalis AM1 Intervention in Bile Acid Modulation and mitigation of liver injury	SUSHMITA PANDEY	Institute of Liver and Biliary Sciences, India
16:10-16:20	FP39	363	Incidence and management of hepatic immune-related adverse events in advanced urologic cancers treated with immune checkpoint inhibitors: A multicenter retrospective study	Youngjoo Park	Pusan National University
16:20-16:30	FP40	332	Quantum Chemical Features Meet Clinical Data for DILI Prediction: Integrating Electronic Density Distribution of Antibiotics with Patient EMR Data	Seongbin Kim	Handong Global University

Free Paper 6 [HBV1]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP41	526	Inverted U-shaped Association Between Hepatitis B Core-Related Antigen and Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B	Ji Eun Han	Ajou University
15:20-15:30	FP42	688	Tenofovir alafenamide vs. tenofovir disoproxil fumarate in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a propensity scores matching analysis	Seong Hee Kang	Korea University
15:30-15:40	FP43	23	Hepatocellular Carcinoma Risk in Treatment-naïve Chronic Hepatitis B patients treated with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate: A Korean nationwide study	Jiwon Yang	University of Ulsan
15:40-15:50	FP44	126	Superior efficacy of besifovir in reducing HCC risk compared to tenofovir in CHB patients: A nationwide cohort study	Yoon E Shin	Soonchunhyang University
15:50-16:00	FP45	345	E-Cigarette Use and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B	Byeong Geun Song	Sungkyunkwan University
16:00-16:10	FP46	79	Prediction of long-term HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients	Hae Lim Lee	The Catholic University of Korea
16:10-16:20	FP47	269	Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-based Treatment With Chronic Hepatitis B	Jeong Heo	Pusan National University
16:20-16:30	FP48	299	Incidence and Risk of Controlled Attenuated Parameter-Based Non-alcoholic Hepatosteatosis Development in Korean Patients with Chronic Hepatitis B	Ye-Rin Chae	Yonsei University

Free Paper 7 [Liver Cancer, Basic]

Time	Abstract No.		Subject	Presenting Author	Institution
15:10-15:20	FP49	286	Aggressiveness-promoting, Fibroblast Activation Protein-STAT3 positive feedback loop is activated by IL-6 in cancer associated fibroblasts of hepatocellular carcinoma	Deok Hwa Seo	The Catholic University of Korea
15:20-15:30	FP50	346	Significance of shelterin component TPP1 upregulation and telomerase activation in the clinico-pathological features of hepatocellular carcinoma	Jung Eun Jang	The Catholic University of Korea
15:30-15:40	FP51	298	AK7 Drives HCC Progression by Enhancing Stemness, EMT, and Hypoxia Adaptation	Geum Ok Baek	Ajou University
15:40-15:50	FP52	535	NADPH oxidase 2 Regulates Epithelial-mesenchymal transition Signaling via Sterol regulatory element-binding protein 2 and Promotes Hepatocellular carcinoma Survival	Hei-Gwon Choi	Chungnam National University
15:50-16:00	FP53	263	Diagnostic and Prognostic impact of circulating exosome microRNA for the early stage of HBV induced HCC	HyoJu Kim	Soonchunhyang University
16:00-16:10	FP54	241	Investigation for prognostic value of circulating tumor DNA by serum KMT2B gene and fragmentation analysis for the HBV-derived HCC after curative resection	Sung Hwan Yoo	Yonsei University
16:10-16:20	FP55	320	Identification of novel links between cirrhosis and hepatocellular carcinoma through mechanisms of immune microenvironment	Eunjeong Kim	Kyungpook National University
16:20-16:30	FP56	25	Association between gut microbial dynamics and clinical outcomes in patients with hepatocellular carcinoma receiving chemoembolization: a prospective study	Jiwon Yang	University of Ulsan



Free Paper Presentation [DAY 3: May 31, 2025 | 13:10-14:30]

Free Paper 8 [Liver Cancer, Clinical 2]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP57	556	A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma incorporating computed tomogram-derived imaging biomarkers	Moon Haeng Hur	Seoul National University
13:20-13:30	FP58	372	Association of Survival with Discordance between Preoperative Radiology and Postoperative Pathology in Patients with Hepatocellular Carcinoma	Woo Sun Rou	Chungnam National University
13:30-13:40	FP59	302	Differential therapeutic effectiveness of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma based on chronic hepatitis B viral activity and etiology: A multicenter cohort study	Yunmi Ko	Seoul National University
13:40-13:50	FP60	487	Identification of Plasma Protein Biomarkers for Predicting Response to Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma	Myung Ji Goh	Sungkyunkwan University
13:50-14:00	FP61	560	Efficacy and Safety of Sorafenib as a Later-Line Treatment in Advanced Hepatocellular Carcinoma: A Phase 2 Study	Youngsu Park	National Cancer Center
14:00-14:10	FP62	723	Can an Ai Predictive Model Be Integrated into Clinical Decision-Making for Predicting Open Conversion in Minimally Invasive Liver Resection?	Boram LEE	Seoul National University
14:10-14:20	FP63	490	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma	Jae Hyun Yoon	Chonnam National University
14:20-14:30	FP64	722	Radiofrequency Ablation versus Minimally Invasive Liver Resection for Small Solitary Hepatocellular Carcinoma (3cm) with MRI Features for Predicting Microvascular Invasion	Na Reum KIM	Yonsei University

Free Paper 9 [HBV2]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP65	561	X/Precore mutational complexity and its impact on HBV replicative activity and histological progression in HBeAg-positive chronic hepatitis B	Jae Mo Han	The Catholic University of Korea
13:20-13:30	FP66	221	An Artificial Intelligence Model Utilizing Imaging Biomarkers on Computed Tomogram to Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B	Hyunjae Shin	Seoul National University
13:30-13:40	FP67	165	Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent	Hyuk Kim	Soonchunhyang University
13:40-13:50	FP68	566	Efficacy and Safety of Switching Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients with Multidrug Resistance	Jaehong Jeong	Yonsei University
13:50-14:00	FP69	309	Comparing Liver Disease Severity and Comorbidity in Patients with HBV Mono-infection and HBV/HDV Co-infection: A Korean Nationwide Population-based Study	Heejoon Jang	Seoul National University
14:00-14:10	FP70	213	The Clinical characteristics among HBV and HDV co-Infected Mongolian patients	Oyungerel Lkhagva-Ochir	Liver Center, Mongolia
14:10-14:20	FP71	401	Prevalence of Viral Hepatitis B, D, and C Among Adolescent and Adult Mongolian Migrants in Seoul, Korea: Implications for Early Screening and Intervention	Wonseok Kang	Sungkyunkwan University
14:20-14:30	FP72	528	Seroprevalence and Clinical Characteristics of Hepatitis D Virus Infection in Korean Patients with Chronic Hepatitis B, Liver Cirrhosis, and Hepatocellular Carcinoma	Eun Sun	Seoul National University

Free Paper 10 [HCV]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP73	248	Changes in Healthcare Costs of Hepatitis C Patients After Introduction of Direct-Acting Antivirals (DAAs) in Korea	Hwa Young Choi	National Cancer Center
13:20-13:30	FP74	238	Cost-Effectiveness of Direct Acting-Antivirals for Chronic Hepatitis C in South Korea	Won Sohn	Sungkyunkwan University
13:30-13:40	FP75	164	Advanced fibrosis and cardiometabolic risk burden increase atherosclerotic cardiovascular events in chronic hepatitis C patients with steatotic liver disease after viral eradication	Ming-Lung Yu	Kaohsiung Medical University, Taiwan
13:40-13:50	FP76	546	Association between hepatitis C virus infection and cardiovascular disease: A nationwide, population-based cohort study in South Korea	Min Kyung Park	Seoul National University
13:50-14:00	FP77	458	Long-Term Hepatocellular Carcinoma Development Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Direct Acting Antivirals	TAE HYUNG KIM	Korea University
14:00-14:10	FP78	580	Real-World Outcomes of Sofosbuvir/Velpatasvir in a Variety of Hepatitis C Patient Populations: A Retrospective Cohort Study	Young Joo Park	Pusan National University
14:10-14:20	FP79	107	Chrono-Optimal Treatments for HIV/HCV Co-infection Yield Comparable Survival Outcomes with HCV Mono-infection	Jeayeon Park	Seoul National University
14:20-14:30	FP80	253	study of safety and efficacy of ledipasvir + sofosbuvir in HCV infection in pregnancy: a real life experience.	Jatinkumar Veljibhai Dhanani	GMERS Medical College, India

Free Paper 11 [MASLD, LC & Others, Basic]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP81	89	Identification of prognostic factors and regulatory pathways in porto-sinusoidal vascular disorder	Won-Mook Choi	University of Ulsan
13:20-13:30	FP82	190	A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population	Ji Eun Kim	Hanyang University
13:30-13:40	FP83	99	FiNi-seq: a quasi-spatial single-cell transcriptome based on physical properties defines early damage niche of the liver	Kwon Yong, Tak	KAIST
13:40-13:50	FP84	533	Spatial Transcriptomics Reveals TAZ Signalling-Mediated Regulation of Liver Fibrosis in MASH	Young-Sun Lee	Korea University
13:50-14:00	FP85	283	Nintedanib Alleviates Metabolic Dysfunction-Associated Steatohepatitis by suppressing THBS1 Expression in activated fibroblasts	Sung Woo Cho	The Catholic University of Korea
14:00-14:10	FP86	542	Targeting CD47 by Engineered Stem Cell-Derived SIRPα-Extracellular Vesicles Ameliorates Liver Fibrosis via Macrophage Reprogramming	Yoon Kyoung Kim	SHIFTBIO
14:10-14:20	FP87	54	PNPLA3 I148M GG Variant Driven Immune Cell Infiltration Associates with Metabolic Dysfunction-Associated Steatotic Liver Disease Progression.	Jung Hoon Cha	The Catholic University of Korea
14:20-14:30	FP88	230	Investigating the Induction Mechanism of the Initial Aging Microenvironment in the Liver through Single-cell Multi-omics Analysis	Seoyeong Lee	KAIST

Free Paper 12 [Liver Transplantation 1]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP89	108	An Increase in Regulatory B Cells Plays a Crucial Role in Achieving Tolerance in Liver Transplantation Patients	Soon Kyu Lee	The Catholic University of Korea
13:20-13:30	FP90	603	Ferulic acid-loaded liposomes mitigate Hepatic Ischemia-Reperfusion Injury in a rat model associated with Liver Transplantation via altering apoptosis, mitochondrial function and TLR-4/NF-B/NLRP3 inflammatory pathway	Niti Singh	CSVTU, India
13:30-13:40	FP91	753	Feasibility of Simultaneous Splenectomy in ABO Incompatible Living Donor Liver Transplantation with Small-for-Size Graft	JaRyung HAN	Daegu Catholic University
13:40-13:50	FP92	387	The Impact of Everolimus Use on Incisional Hernia in Liver Transplant Patients	Eunjin Lee	Sungkyunkwan University School of Medicine
13:50-14:00	FP93	324	Transcriptomic Profiling of Personalized Immunosuppressant Modelling to Prevent Acute Cellular Rejection (ACR) in Pediatric Liver Transplant Recipients.	Anindya Amanda Damayanti	Islamic Indonesia University, Indonesia
14:00-14:10	FP94	716	Quality Score : Development of Integrative Prognostic Index for Living Donor Liver Using Multicentric Registry Data	Deok-Gie KIM	Yonsei University
14:10-14:20	FP95	729	Adult-to-Adult Right Lobe Graft Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure: A Single-Centre Retrospective Study in Vietnam	The Duy NGUYEN	Vin University, Vietnam
14:20-14:30	FP96	720	Safety of Living Right Liver Donors Aged 45 and Older: Risks and Outcomes for Donors and Recipients	Sang-Hoon KIM	University of Ulsan

Free Paper 13 [Liver Transplantation 2]

Time	Abstract No.		Subject	Presenting Author	Institution
13:10-13:20	FP97	721	Severity and Pattern of Bile Duct Complications after Donor Right Hepatectomy: Open versus Minimally Invasive Approaches	Na Reum KIM	Yonsei University
13:20-13:30	FP98	524	Prognostic Concordance Between LI-RADS Imaging and Pathology for Liver Transplant Eligibility in HCC: Results from 1,059 Patients	Yeongseok Hwang	University of Ulsan
13:30-13:40	FP99	664	Aging in Place for Elderly Undergo Liver Transplantation: How Informal Care Could Help Maintaining Higher Quality of Life?	Hepri Ardianson	The Pranala Institute, Indonesia
13:40-13:50	FP100	728	Development and Optimization of Transplant Surgeon-Innovated Evmp: Validation in a Porcine Dcd Liver Transplant Model	Mun Chae CHOI	Armed Forces Capital Hospital
13:50-14:00	FP101	380	Prediction Of Early Risk Of Patient Survival Following Liver Transplant Based On Lifestyle Factors Via Machine Learning Models	Manvendra	HMFA MIET, India
14:00-14:10	FP102	760	Development of Immune-Evasive Meta-Soft Organ Modules through Advanced Cell Engineering and Assembly Technology	Hee Ju KIM	Hanyang University
14:10-14:20	FP103	47	Rehabilitation for Fatigue After Liver Transplantation: Effects of Exercise and Physical Activity Counseling	Ganesh Kumar Singh	Army Forced Hospital, Nepal
14:20-14:30	FP104	714	Clinical Outcomes of 90 Cases of Post-Transplant Lymphoproliferative Disorder (PTLD) after Liver Transplantation: A 24-Years Single- Center Experience	Sung-Min KIM	University of Ulsan